BAMS
ESPR

Bellevue Asset Management (Switzerland)’s Esperion Therapeutics ESPR Stock Holding History

Bellevue Asset Management (Switzerland)’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		$890K Hold
40,000
– – 0.14% 103
2015
Q3 		$944K Buy
40,000
+13,000
+48% +$816K 0.15% 107
2015
Q2 		$2.21M Buy
+27,000
New +$2.64M 0.31% 80

Other funds holding ESPR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Bellevue Asset Management (Switzerland)'s ESPR Position: Q4 2015 in Review

Bellevue Asset Management (Switzerland) held its Esperion Therapeutics (ESPR) position steady in Q4 2015 at 40,000 shares worth $890K. The position accounts for 0.14% of the portfolio, ranked #103.

Bellevue Asset Management (Switzerland) first reported a position in ESPR in Q2 2015 and has held it in 3 quarters since. The position peaked at $2.21M in Q2 2015. 113 funds tracked by Wall St. Rank hold ESPR as of Q4 2015.

  • Bellevue Asset Management (Switzerland) held 40,000 shares of Esperion Therapeutics worth $890K as of Q4 2015.
  • Bellevue Asset Management (Switzerland) left its Esperion Therapeutics share count unchanged in Q4 2015.
  • Esperion Therapeutics made up 0.14% of Bellevue Asset Management (Switzerland)'s portfolio in Q4 2015, its #103 holding.
  • Bellevue Asset Management (Switzerland) first reported a position in Esperion Therapeutics in Q2 2015 and has held it in 3 quarters since.
  • Bellevue Asset Management (Switzerland)'s Esperion Therapeutics position peaked at $2.21M in Q2 2015.
  • 113 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2015.

Based on Bellevue Asset Management (Switzerland)'s 13F filing for Q4 2015, filed 12 Feb 2016.